rs12206094 — FOXO3

Functional FOXO3 intronic variant with allele-specific CTCF binding and IGF-1-reversible enhancer activity; T allele raises longevity odds ~22% across European cohorts

See your personal result for FOXO3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

FOXO3's Mechanistic Longevity Variant — Enhancer Activity and the IGF-1 Connection

FOXO3 is the most consistently replicated longevity gene in humans — the only gene besides APOE whose protective associations have held across independent populations on multiple continents. Most research has focused on rs2802292 and related intronic variants, but the FOXO3 locus harbors a second layer of regulatory complexity. Flachsbart et al. 201711 Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 identified rs12206094 as one of two variants with direct experimental evidence for allele-specific function — making it one of the small number of FOXO3 longevity variants with a known molecular mechanism rather than a statistical association alone.

The T allele of rs12206094 is the longevity-associated minor allele, carried by approximately 30% of people globally. In a meta-analysis spanning three European longevity cohorts (German centenarians, French nonagenarians, and Danish oldest-old), each copy of the T allele was associated with a 22% increase in odds of exceptional longevity (OR = 1.219, p = 1.31×10⁻⁶). The effect was strongest in German centenarians aged 100–110 (OR = 1.306), where the T allele frequency climbed from 28.7% in controls to 34.5% in centenarians.

The Mechanism

rs12206094 sits in intron 2 of FOXO3, 94.5 kilobases from a second functional variant (rs4946935) in the same locus. The two variants are in moderate linkage disequilibrium (r² = 0.61), meaning they travel together on longevity haplotypes but can also be inherited independently — important context for understanding their additive but non-redundant effects.

The mechanistic story for rs12206094 centers on CTCF22 CTCF
CCCTC-binding factor, a master genome organizer that regulates chromatin looping, insulation of gene domains, and transcription factor access. Electrophoretic mobility shift assays showed that CTCF binds more strongly to the common C allele than to the longevity T allele. This is initially counterintuitive — a protective allele with weaker transcription factor binding — but the key insight is that CTCF at this site appears to act as an insulator or repressor rather than an activator. Reducing CTCF occupancy at the T allele may relieve local chromatin compaction, opening the locus to activating inputs.

Luciferase reporter assays in pancreatic and Jurkat T-cell lines confirmed that both alleles drive enhancer activity above baseline, but the T allele drives significantly greater promoter activity (p < 0.05). Critically, this enhanced activity is reversed by IGF-1 treatment — linking the variant directly to insulin/IGF-1 signaling (IIS), the most conserved longevity pathway from nematodes to humans. Under high-IGF-1 conditions (simulating caloric excess), the longevity allele's advantage is blunted; under low-IGF-1 conditions (caloric restriction or fasting), the T allele's enhanced enhancer activity drives higher FOXO3 expression.

eQTL data from multiple tissue databases confirmed the molecular phenotype: carriers of the T allele show higher FOXO3 mRNA expression across multiple tissues including brain regions, pancreas, prostate, and testis. This expression advantage translates into greater FOXO3 protein availability to activate downstream protective programs — antioxidant gene induction, DNA repair, autophagy, and attenuation of inflammatory signaling.

The Evidence

The Flachsbart 2017 study combined resequencing of the full FOXO3 locus with association testing in three independent European cohorts:

  • German cohort: 717 long-lived individuals (≥95 years) vs. 1,111 controls; centenarian OR = 1.306 (p = 0.001), with stronger effects in males (OR = 1.469)
  • French cohort: 536 individuals aged 91–115 years vs. 534 controls; OR = 1.160 (p = 0.008)
  • Danish cohort: 1,088 individuals aged 92–101 years vs. 736 controls; OR = 1.235 (p = 0.012)
  • Meta-analysis: OR = 1.219, p = 1.31×10⁻⁶ — well past genome-wide significance

Functional validation went beyond statistics. The CTCF binding difference was demonstrated in electrophoretic mobility shift assays (EMSAs) with nuclear extracts. Luciferase reporter assays used cells treated with and without IGF-1 to show the hormonal context-dependence. eQTL associations were confirmed in public databases spanning tens of thousands of tissue samples. This combination of population genetics, protein binding, reporter assays, and expression data meets the bar for a mechanistically characterized longevity variant.

The variant has since appeared in studies of other phenotypes — including noise-induced hearing loss and ankylosing spondylitis susceptibility — consistent with FOXO3's broad role in inflammation, oxidative stress response, and tissue homeostasis.

Practical Actions

The T allele's mechanism — blunted by high IGF-1, amplified by low IGF-1 — provides a clear dietary and lifestyle leverage point. Intermittent fasting, time-restricted eating, and low-glycemic diets all reduce circulating IGF-1, which may amplify the T allele's enhancer advantage. This is consistent with the broader literature showing that caloric restriction and IGF-1 pathway modulation extend lifespan in model organisms via FOXO3 activation.

For CT heterozygotes (42% of people), each T allele adds a partial boost to FOXO3 expression. The same lifestyle strategies that work for TT homozygotes apply, with proportionally smaller expected magnitude. For CC homozygotes, the protective variant is absent, but FOXO3 activation is still achievable through behavioral means — the gene responds to the same metabolic signals regardless of this variant's baseline effect.

Interactions

rs12206094 and rs4946935 are 94.5 kb apart with moderate LD (r² = 0.61) and operate through distinct molecular mechanisms — rs12206094 via CTCF binding dynamics, rs4946935 via SRF (serum response factor) binding. Carrying longevity alleles at both variants does not produce additive benefit; the Flachsbart study observed a negative epistatic interaction, suggesting the two regulatory elements share downstream effectors or compete for the same activating complexes.

rs2802292, the most studied FOXO3 longevity SNP in intron 2 (r² ≈ 0.00 with rs12206094), operates via a completely independent mechanism (HSF1 binding), making the FOXO3 locus a rare example of at least three functionally distinct longevity-associated regulatory elements in a single gene.

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Genotype Normal

Common FOXO3 genotype — longevity variant absent

You carry two copies of the common C allele at rs12206094. This is the most frequent genotype worldwide, carried by about 49% of people. The T allele's enhancer advantage and higher FOXO3 mRNA expression are not present at baseline, but FOXO3 expression remains highly responsive to lifestyle inputs — particularly fasting, low-glycemic eating, and exercise — through other regulatory elements in the gene.

CT One Longevity Allele Beneficial

One copy of the FOXO3 longevity enhancer variant

The T allele at rs12206094 reduces CTCF occupancy at this intronic site, which appears to relieve local chromatin compaction and enhance access for activating transcription factors. Luciferase reporter assays confirmed the T allele drives significantly greater promoter activity than the C allele — but critically, this advantage is reversed by IGF-1 treatment. This means your T allele's benefit is most pronounced in metabolic states with low insulin/IGF-1 signaling: fasting, aerobic exercise, and low-glycemic eating. As a CT heterozygote, you have one copy of this advantage, with an intermediate effect between CC and TT.

TT Two Longevity Alleles Beneficial

Two copies of the FOXO3 longevity enhancer variant

As a TT homozygote, both copies of this intronic regulatory region carry the allele associated with reduced CTCF binding and enhanced basal transcriptional activity at the FOXO3 locus. eQTL data confirm higher FOXO3 mRNA expression in brain, pancreas, prostate, testis, and other tissues for T allele carriers, with TT homozygotes showing the strongest expression signal.

The critical modifier is IGF-1: luciferase assays showed that IGF-1 treatment reverses the T allele's enhancer advantage. This means TT individuals have the most to gain from low-IGF-1 metabolic states (fasting, caloric restriction, low-glycemic diet) and the most to lose from chronic hyperinsulinemia or very high protein intakes that sustain elevated IGF-1. The variant's evolutionary context is illuminating — ancestral European hunter-gatherers showed higher T allele frequencies than contemporary Europeans, consistent with selection favoring this allele under lower caloric availability.

Note that rs12206094 and the second functional FOXO3 variant rs4946935 show a negative epistatic interaction — carriers of longevity alleles at both simultaneously do not gain additive benefit. Your TT status at rs12206094 is fully informative independent of rs4946935 genotype.